|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | -.--% |
|
-.--% | -40.00% |
| Market Cap | 918K 659K 570K 533K 487K 62.85M 933K 6.25M 2.45M 31.44M 2.47M 2.42M 105M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.38M 1.19M 1.11M 1.02M 131M 1.95M 13.06M 5.12M 65.65M 5.17M 5.05M 219M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
| 3 months | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -40.00% |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.04 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.2 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 2018-08-02 |
Mahmoud Aziz
PSD | President | - | 2021-05-20 |
Danny Wayne Lee
DFI | Director of Finance/CFO | - | 2020-12-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 2018-08-02 |
Jamie Lewin
BRD | Director/Board Member | 76 | 2019-03-10 |
Kevin Bottomley
BRD | Director/Board Member | 44 | 2019-09-04 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 9/9/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -57.14% | -75.00% | 659K | ||
| -0.03% | -2.32% | +22.53% | +68.67% | 49.03B | ||
| -1.14% | +13.15% | +60.80% | +127.29% | 42.33B | ||
| +0.27% | -0.37% | -1.22% | +15.93% | 12.43B | ||
| +0.43% | -0.69% | +19.53% | +69.15% | 11.68B | ||
| +3.84% | +0.19% | +30.98% | +140.74% | 9.12B | ||
| +3.81% | +8.39% | +22.04% | +39.32% | 7.15B | ||
| +1.62% | +1.47% | +41.67% | -12.77% | 7.09B | ||
| -1.22% | +0.78% | +11.47% | +171.70% | 6.76B | ||
| +0.03% | +8.29% | -24.59% | +28.71% | 5.95B | ||
| Average | +0.36% | -0.35% | +12.61% | +57.37% | 15.15B | |
| Weighted average by Cap. | -0.08% | +1.73% | +30.08% | +82.92% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.28 0 0.03 0.01 0.14 0.01 0.01 0.46 | - |
| Net income | -73.2K -52.52K -45.47K -42.5K -38.84K -5.01M -74.34K -498K -196K -2.51M -197K -193K -8.35M | -335K -240K -208K -195K -178K -22.93M -340K -2.28M -895K -11.47M -903K -883K -38.21M |
| Net Debt | 804K 577K 500K 467K 427K 55.04M 817K 5.48M 2.15M 27.53M 2.17M 2.12M 91.7M | 999K 717K 621K 580K 530K 68.39M 1.01M 6.8M 2.67M 34.21M 2.69M 2.63M 114M |
Employees
4,000
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















